Neumora Therapeutics公司已决定终止其核心候选药物Navacaprant的后续开发工作。这一决定源于该药物在两项关键的三期临床试验——Koastal-2与Koastal-3中未能达到预设的主要疗效终点。
两项试验的数据均显示，Navacaprant在治疗重度抑郁症方面，其疗效与安慰剂相比未显示出具有统计学意义的显著优势。面对这一结果，公司管理层经过审慎评估，认为继续推进该项目的商业前景有限，故而作出了终止研发的战略决策。
此次研发挫折无疑对Neumora Therapeutics构成了重大打击。Navacaprant曾被公司寄予厚望，视为其产品管线中极具潜力的重磅资产。研发项目的终止不仅意味着前期投入的巨大资源付诸东流，也可能引发市场对其未来增长潜力的重新评估。
公司表示，未来将把研发资源与战略重心重新配置到管线中的其他候选药物上，以期寻求新的突破口。然而，核心项目的折戟，短期内势必对公司的股价与市场信心带来考验。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.